AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

May 20, 2013

AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy

NORTH CHICAGO, Ill., May 20, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease (CKD) and type 2 diabetes.  SONAR is a large, multinational, double-blind, placebo-controlled clinical study that is expected to enroll more than 4,000 patients with diabetic nephropathy.  The study will evaluate atrasentan's impact on renal outcomes, such as the onset of end-stage renal disease (ESRD), as defined by need for chronic dialysis, transplant or death due to renal failure progression.i

May 17, 2013

AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease

NORTH CHICAGO, Ill. and MECHELEN, Belgium, May 17, 2013 /PRNewswire/ -- Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV) announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease.  Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3.  Upon successful completion of the study, expected in Q2 2015, AbbVie will pay Galapagos $50 million.  The terms of the collaboration extension are in addition to previously agreed upon financial terms.  AbbVie will be responsible for funding and performing clinical development beyond Phase 2, and completing regulatory and commercialization activities.

May 15, 2013

AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting

NORTH CHICAGO, Ill., May 15, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data evaluating several investigational compounds in the company's oncology pipeline will be presented at the upcoming 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 - June 4, Chicago.  Data being presented include the results from two clinical trials evaluating the safety and efficacy of ABT-199, a BCL-2 selective inhibitor, in chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL).

May 14, 2013

AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease

NORTH CHICAGO, Ill. and SAN CARLOS, Calif., May 14, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Alvine Pharmaceuticals, a leader in celiac disease therapeutics development, announced today that they have entered into a global collaboration to develop a novel oral treatment for patients with celiac disease, currently in Phase 2 development.  This collaboration builds on AbbVie's expertise and leadership in the field of gastroenterology with its on-market products to treat Crohn's disease, ulcerative colitis, and diseases associated with exocrine pancreatic insufficiency.

May 07, 2013

AbbVie to Present at Bank of America Merrill Lynch 2013 Health Care Conference

NORTH CHICAGO, Ill., May 7, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Merrill Lynch 2013 Health Care Conference on Tuesday, May 14, 2013.  Bill Chase, executive vice president and chief financial officer, and John M. Leonard, M.D., senior vice president and chief scientific officer, will take part in a question and answer session at 12:40 p.m. Central time.

May 06, 2013

AbbVie's Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration

NORTH CHICAGO, Ill., May 6, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its investigational direct-acting antiviral (DAA) combination with and without ribavirin for the treatment of genotype 1 (GT1) hepatitis C virus (HCV) infection has been designated as a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA).

May 01, 2013

AbbVie CF Scholarship Application Now Available for Exceptional Undergraduate and Graduate Students with Cystic Fibrosis

NORTH CHICAGO, Ill., May 1, 2013 /PRNewswire/ -- AbbVie today announced that undergraduate and graduate students living with cystic fibrosis (CF) can now apply for the AbbVie CF Scholarship for the 2013-2014 academic school year.  

Apr 26, 2013

AbbVie Reports First-Quarter 2013 Financial Results

NORTH CHICAGO, Ill., April 26, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced financial results for the first quarter ended March 31, 2013.

Apr 23, 2013

New Data from AbbVie's Phase IIb Aviator Trial Demonstrate High Sustained Viral Response Rates Across Multiple Patient Types with HCV Genotype 1

AMSTERDAM, April 23, 2013 /PRNewswire/ -- (NYSE: ABBV)  – Results from "Aviator,"  AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection, continue to demonstrate high sustained viral response (SVR) rates against genotype 1 HCV, across patient types. Data show greater than 90 percent SVR were achieved in patients new to treatment and in patients who had previously failed treatment with pegylated interferon and ribavirin (null responders). In addition, similar high SVR rates observed after 12 and 24 weeks of treatment in the Phase IIb trial reinforce the adequacy of the 12-week treatment duration for the investigational interferon-free, triple DAA combination.  The triple-DAA combination is currently being studied in Phase III clinical trials. Results will be featured in the official press conference at the 2013 International Liver Congress® (ILC) in Amsterdam on Wednesday, April 24 at 11:00 CEST and presented on Thursday, April 25.

Apr 17, 2013

Sofia Vergara Encourages Individuals with Hypothyroidism to "Follow the Script"

NORTH CHICAGO, Ill., April 17, 2013 /PRNewswire/ -- (NYSE: ABBV) - Emmy-nominated actress Sofia Vergara is helping to raise awareness about the importance of diagnosing and treating hypothyroidism, a thyroid condition that affects millions of Americans, through a new campaign called "Follow the Script." The campaign, made possible by AbbVie, aims to educate individuals with hypothyroidism about the importance of being consistent with the treatment their doctor prescribes, and provides a "script" to ensure they consistently receive the medication prescribed by their doctor when they visit the pharmacy.